MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-06-2023
Aridis Pharmaceuticals Retained Earnings 2011-2026 | ARDS
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Aridis Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -196 M | -165 M | - | -101 M | -71.1 M | -47.6 M | -20.2 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -20.2 M | -196 M | -100 M |
Quarterly Retained Earnings Aridis Pharmaceuticals
| 2023-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -190 M | -196 M | -189 M | -181 M | -173 M | -165 M | -156 M | -135 M | -130 M | -123 M | -123 M | -123 M | -123 M | -101 M | -101 M | -101 M | -101 M | -71.1 M | -71.1 M | -71.1 M | -71.1 M | -47.6 M | -47.6 M | -47.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -47.6 M | -196 M | -118 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M |  USA |
 |
Agenus
AGEN
|
-1.96 B | $ 3.27 | -1.8 % | $ 1.17 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
-562 M | $ 29.33 | -2.98 % | $ 1.7 B | USA |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
Akebia Therapeutics
AKBA
|
-1.68 B | $ 1.26 | -3.44 % | $ 324 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-247 M | $ 0.24 | 1.1 % | $ 5.73 B |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Aldeyra Therapeutics
ALDX
|
-484 M | $ 5.49 | 0.52 % | $ 330 M | USA |
 |
AgeX Therapeutics
AGE
|
-131 M | - | -10.17 % | $ 12.2 K | USA |
 |
Alector
ALEC
|
-972 M | $ 2.26 | -7.2 % | $ 233 M | USA |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
Aligos Therapeutics
ALGS
|
-487 M | $ 7.02 | -0.21 % | $ 451 M | USA |
 |
Alkermes plc
ALKS
|
-735 M | $ 29.32 | -2.61 % | $ 4.83 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
-1.56 B | $ 2.57 | -7.73 % | $ 403 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
-6.7 B | $ 330.95 | -0.59 % | $ 43.4 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Altimmune
ALT
|
-561 M | $ 4.2 | -2.55 % | $ 298 M | USA |
 |
ALX Oncology Holdings
ALXO
|
-621 M | $ 2.11 | 0.09 % | $ 110 M | USA |
 |
Amgen
AMGN
|
-25.1 B | $ 387.85 | 0.03 % | $ 209 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
667 M | $ 20.22 | -0.05 % | $ 945 M | USA |
 |
Amarin Corporation plc
AMRN
|
-1.59 B | $ 13.62 | -1.3 % | $ 5.55 B | Irlanda |
 |
AIM ImmunoTech
AIM
|
-381 M | $ 0.92 | 5.25 % | $ 44.2 M | USA |
 |
AnaptysBio
ANAB
|
-759 M | $ 54.61 | -0.8 % | $ 1.55 B | USA |
 |
Anika Therapeutics
ANIK
|
128 M | $ 14.44 | 0.53 % | $ 212 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
-100 M | $ 75.31 | 1.91 % | $ 1.45 B | USA |
 |
Annexon
ANNX
|
-711 M | $ 5.38 | -3.93 % | $ 739 M | USA |
 |
Annovis Bio
ANVS
|
-110 M | $ 2.6 | -2.99 % | $ 23.5 M | USA |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Apellis Pharmaceuticals
APLS
|
-3.01 B | $ 20.53 | -2.05 % | $ 2.59 B | USA |
 |
Aptorum Group Limited
APM
|
-72.4 M | $ 0.78 | -0.67 % | $ 4.25 M | China |
 |
AIkido Pharma
AIKI
|
-223 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |
 |
Aprea Therapeutics
APRE
|
-308 M | $ 0.88 | -3.71 % | $ 3.18 M | USA |
 |
Aptevo Therapeutics
APVO
|
-248 M | $ 7.28 | -0.55 % | $ 2.01 M | USA |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-246 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aquestive Therapeutics
AQST
|
-363 M | $ 3.99 | -0.15 % | $ 346 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-449 M | $ 8.11 | -1.44 % | $ 219 M |  Israel |
 |
Ardelyx
ARDX
|
-947 M | $ 6.32 | -3.54 % | $ 1.52 B | USA |
 |
Aileron Therapeutics
ALRN
|
-351 M | - | 10.36 % | $ 9.8 M | USA |
 |
argenx SE
ARGX
|
-861 M | $ 762.51 | -0.58 % | $ 25 B |  Niderland |